News | December 04, 2008

New Study to Validate the Effectiveness of 320-Detector Row CT as Compared to SPECT

December 5, 2008 - As the next phase in validating advanced computed tomography technology in a clinical setting, Toshiba Medical Systems Corp. will support CORE 320, the largest worldwide multi-center trial comparing the effectiveness of 320-detector row dynamic volume CT to SPECT technology in cardiac evaluation.

The trial will examine whether the combination of CT angiography and myocardial perfusion can identify coronary stenoses that are less than or equal to 50 percent by quantitative coronary analysis (QCA) and correspond to a SPECT perfusion defect. CORE 320 will begin in December 2008.

The Aquilion ONE, the dynamic volume CT system to be used in CORE 320. The trial will be lead by primary investigator Dr. Joao A. C. Lima of Johns Hopkins University School of Medicine, in Baltimore, MD. Johns Hopkins University will also serve as the core site for CT. Dr. Marcelo Di Carli of Brigham and Women’s Hospital, a Harvard teaching hospital, in Boston, MA. will serve as core site for SPECT. Additional investigation sites will be announced in the coming months.

“We expect CORE 320 findings to impact the way the medical community views the role of dynamic volume CT in the diagnosis and treatment of life-threatening diseases,” explained Toki. “These results eventually could impact they way patients are diagnosed and treated.”

Toshiba believes in developing technology that helps improve patient outcomes and as such, sponsors clinical trials to assure new technology adds true value to the healthcare system and patient. CORE 320 is the next phase of that validation strategy.

Prior to CORE 320, Toshiba funded the CorE 64 (Coronary Evaluation using multidetector 64 CT) trial, an international multi-center trial to validate multidetector CT’s ability to detect coronary artery disease (CAD) as compared to conventional coronary angiography (CCA). On Nov. 26, 2008, the New England Journal of Medicine published the promising results of the CorE 64 trial stating “multidetector CT angiography accurately identifies the presence and severity of obstructive coronary artery disease and subsequent revascularization in symptomatic patients.”

Another Toshiba trial, faCTor64, the Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following CorE 64, is being conducted at Intermountain Healthcare’s Intermountain Medical Center in Salt Lake City. More than 1,000 patients from Utah, women older than 55 and men older than 50 are enrolled in the faCTor64 study. Intermountain Healthcare CORE 320 Multi-Center Trial used its diabetes registry of 30,000 patients, who have already received best-practice diabetic care, as a resource to enroll patients.

Introduced in November 2007, dynamic volume CT scans an entire organ in a single pass and produces 4D videos that show an organ’s structure, its movement and blood flow. In comparison, a 64-slice, 128-slice or 256-slice CT scan can only capture a portion of an organ in a single pass, requiring physicians to “stitch together” multiple scans of an organ to get a full image. The new technology helps reduce multiple exposures to radiation and exam time.

For more information, visit www.medical.toshiba.com

Related Content

Study Shows Biomarker Panel Boosts Lung Cancer Risk Assessment for Smokers
News | Lung Cancer | July 16, 2018
A four-protein biomarker blood test improves lung cancer risk assessment over existing guidelines that rely solely upon...
iSchemaView Brings RAPID Imaging Platform to Australia and New Zealand
News | Stroke | July 13, 2018
iSchemaView has signed Diagnostic Imaging Australia (DIA) to be the exclusive distributor for the RAPID cerebrovascular...
Zebra Medical Vision Announces FDA 510(k) Clearance of Coronary Calcium Algorithm
Technology | Computed Tomography (CT) | July 12, 2018
Zebra Medical Vision has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Coronary...
IAC Awards First CT Accreditation for a Mobile Stroke Unit
News | Computed Tomography (CT) | July 09, 2018
The Intersocietal Accreditation Commission (IAC) recently recognized the University of Tennessee Health Science Center...
HeartFlow Announces New Commercial Coverage With UnitedHealthcare
News | Computed Tomography (CT) | July 03, 2018
HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45...
Peter Juodka, RT(CT) operates the 16-slice Siemens Somatom Scope CT scanner in the mobile stroke unit to assess stroke patients immediately at the call site.

Peter Juodka, RT(CT) operates the 16-slice Siemens Somatom Scope CT scanner in the mobile stroke unit to assess stroke patients immediately at the call site.

Feature | Computed Tomography (CT) | July 03, 2018 | By Jeff Zagoudis
Stroke is the fifth leading cause of death in the United States, responsible for more than 140,000 deaths in some of
Neusoft Medical Systems USA Introducing NeuViz 16 Essence CT at AHRA 2018
Technology | Computed Tomography (CT) | June 27, 2018
At the 2018 Association for Medical Imaging Management (AHRA) Annual Meeting, July 22-25 in Orlando, Fla., Neusoft...
Smoking and Diabetes Linked to Brain Calcifications
News | Neuro Imaging | June 26, 2018
People who smoke or have diabetes may be at increased risk of calcifications in a region of the brain crucial to memory...
Post-Mortem CT Angiography Illuminates Causes of Death
News | CT Angiography (CTA) | June 25, 2018
Computed tomography (CT) angiography is a useful adjunct to autopsy that is likely to increase the quality of post-...
Overlay Init